Business Segment Information (Tables)

3 Months Ended

Jul. 31, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

Three Months Ended July 31, 2012	Personalized Oncology Solutions (POS)			Translational Oncology Solutions (TOS)			Unallocated Corporate Overhead			Consolidated
Net revenue	$	918		$	1,188		$	-		$	2,106
Direct cost of services		(717	)		(691	)		-			(1,408	)
Sales and marketing costs		(435	)		(192	)		-			(627	)
Other operating expenses		-			(363	)		(568	)		(931	)
Stock- based compensation expense (1)		-			-			(739	)		(739	)
Segment profit (loss)	$	(234	)	$	(58	)	$	(1,307	)	$	(1,599	)

Three Months Ended July 31, 2011	Personalized Oncology Solutions (POS)			Translational Oncology Solutions (TOS)			Unallocated Corporate Overhead			Consolidated
Net revenue	$	601		$	1,033		$	-		$	1,634
Direct cost of services		(483	)		(419	)		-			(902	)
Sales and marketing costs		(369	)		(245	)		-			(614	)
Other operating expenses		-			(517	)		(801	)		(1,318	)
Stock- based compensation expense (1)		-			-			(1,014	)		(1,014	)
Segment profit (loss)	$	(251	)	$	(148	)	$	(1,815	)	$	(2,214	)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.